Hepatocellular Carcinoma with Distant Metastasis Cured by 20-Day Sorafenib Treatment

Overview

Journal Case Rep Gastroenterol

Publisher Karger

Specialty Gastroenterology

Date 2021 Oct 7

PMID 34616264

Citations 3

Authors

Seok Bae Kim

Affiliations

Soon will be listed here.

Abstract

There are only 13 cases of complete remission after sorafenib use in advanced hepatocellular carcinoma (HCC) worldwide. We herein report a rarer case in which the patient was cured after only 20 days of sorafenib use. A 61-year-old male patient was diagnosed with a huge HCC. The mass occupied almost the whole of the right hepatic lobe and a portion of segment 4. We performed extended right hepatectomy for cure. However, 3.5-cm-sized subcarinal lymph node metastasis was detected at 15 months after operation. We prescribed sorafenib 400 mg bid for palliative treatment. The patient had severe fever, pain, and blisters on the hands and feet, so the patient stopped taking it after 20 days. Subcarinal lymph node disappeared on chest computed tomography after 3 months, and there was no evidence of recurrence for a year.

Citing Articles

Deciphering the multifaceted role of microRNAs in hepatocellular carcinoma: Integrating literature review and bioinformatics analysis for therapeutic insights.

Rahdan F, Saberi A, Saraygord-Afshari N, Hadizadeh M, Fayeghi T, Ghanbari E Heliyon. 2024; 10(20):e39489.

PMID: 39498055 PMC: 11532857. DOI: 10.1016/j.heliyon.2024.e39489.

Unusual extrahepatic metastatic site of hepatocellular carcinoma with post-therapy disseminating metastases presenting as a primary soft tissue sarcoma: case report.

Liu K, Chang Y, Lin Y, Chang J Ann Med Surg (Lond). 2024; 86(9):5501-5508.

PMID: 39239049 PMC: 11374306. DOI: 10.1097/MS9.0000000000002307.

Bioactive xanthones, benzophenones and biphenyls from mangosteen root with potential anti-migration against hepatocellular carcinoma cells.

Choodej S, Koopklang K, Raksat A, Chuaypen N, Pudhom K Sci Rep. 2022; 12(1):8605.

PMID: 35597781 PMC: 9124209. DOI: 10.1038/s41598-022-12507-8.

References

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

Wang S, Byrnes A, Verma S, Pancoast J, Rixe O . Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: a case report. Target Oncol. 2010; 5(1):59-63. DOI: 10.1007/s11523-010-0133-x. View

Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D . Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006; 66(24):11851-8. DOI: 10.1158/0008-5472.CAN-06-1377. View

Chelis L, Ntinos N, Souftas V, Deftereos S, Xenidis N, Chamalidou E . Complete response after sorafenib therapy for hepatocellular carcinoma in an HIV-HBV co infected patient: Possible synergy with HAART ? A case report. Med Oncol. 2010; 28 Suppl 1:S165-8. DOI: 10.1007/s12032-010-9669-y. View

Kim M, Jin Y, Lee J, Lee J, Kim Y, Lee S . Complete remission of advanced hepatocellular carcinoma by sorafenib: A case report. World J Gastrointest Oncol. 2013; 5(2):38-42. PMC: 3613770. DOI: 10.4251/wjgo.v5.i2.38. View

Liu D, Liu A, Peng J, Hu Y, Feng X . Case analysis of complete remission of advanced hepatocellular carcinoma achieved with sorafenib. Eur J Med Res. 2015; 20:12. PMC: 4323035. DOI: 10.1186/s40001-015-0085-9. View

So B, Bekaii-Saab T, Bloomston M, Patel T . Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: a case report. J Hematol Oncol. 2008; 1:18. PMC: 2575202. DOI: 10.1186/1756-8722-1-18. View

Yoshida T, Hisamoto T, Akiba J, Koga H, Nakamura K, Tokunaga Y . Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors. Oncogene. 2006; 25(45):6056-66. DOI: 10.1038/sj.onc.1209635. View

Sacco R, Bargellini I, Gianluigi G, Bertini M, Bozzi E, Altomare E . Complete response for advanced liver cancer during sorafenib therapy: case report. BMC Gastroenterol. 2011; 11:4. PMC: 3036648. DOI: 10.1186/1471-230X-11-4. View

10.

Inuzuka T, Nishikawa H, Sekikawa A, Takeda H, Henmi S, Sakamoto A . Complete response of advanced hepatocellular carcinoma with multiple lung metastases treated with sorafenib: a case report. Oncology. 2012; 81 Suppl 1:152-7. DOI: 10.1159/000333279. View

11.

Curtit E, Thiery-Vuillemin A, Nguyen T, Heyd B, Pivot X, Di Martino V . Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma: a case report. J Clin Oncol. 2011; 29(12):e330-2. DOI: 10.1200/JCO.2010.32.6785. View

12.

Yeganeh M, Finn R, Saab S . Apparent remission of a solitary metastatic pulmonary lesion in a liver transplant recipient treated with sorafenib. Am J Transplant. 2009; 9(12):2851-4. DOI: 10.1111/j.1600-6143.2009.02860.x. View

13.

Shao Y, Lin Z, Hsu C, Shen Y, Hsu C, Cheng A . Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer. 2010; 116(19):4590-6. DOI: 10.1002/cncr.25257. View

14.

Forner A, Llovet J, Bruix J . Hepatocellular carcinoma. Lancet. 2012; 379(9822):1245-55. DOI: 10.1016/S0140-6736(11)61347-0. View

15.

Bruix J, Reig M, Sherman M . Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. Gastroenterology. 2016; 150(4):835-53. DOI: 10.1053/j.gastro.2015.12.041. View

16.

Cheng A, Kang Y, Chen Z, Tsao C, Qin S, Kim J . Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2008; 10(1):25-34. DOI: 10.1016/S1470-2045(08)70285-7. View

17.

Irtan S, Chopin-Laly X, Ronot M, Faivre S, Paradis V, Belghiti J . Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection. Liver Int. 2011; 31(5):740-3. DOI: 10.1111/j.1478-3231.2010.02441.x. View

18.

Vincenzi B, Santini D, Russo A, Addeo R, Giuliani F, Montella L . Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist. 2010; 15(1):85-92. PMC: 3227883. DOI: 10.1634/theoncologist.2009-0143. View

19.

Lulla P, Brammer J, Bandeali S, Lynch G . Sustained complete remission of metastatic hepatocellular carcinoma with single agent sorafenib. J Gastrointest Cancer. 2012; 44(1):98-101. DOI: 10.1007/s12029-012-9438-6. View

20.

Mizukami H, Kagawa T, Arase Y, Nakahara F, Tsuruya K, Anzai K . Complete response after short-term sorafenib treatment in a patient with lymph node metastasis of hepatocellular carcinoma. Case Rep Oncol. 2013; 5(2):380-4. PMC: 3409511. DOI: 10.1159/000341259. View